DekaBank Deutsche Girozentrale Cuts Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

DekaBank Deutsche Girozentrale decreased its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 54.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,600 shares of the company's stock after selling 16,000 shares during the quarter. DekaBank Deutsche Girozentrale's holdings in BeiGene were worth $2,434,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Baillie Gifford & Co. boosted its stake in shares of BeiGene by 17.9% in the third quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company's stock worth $696,384,000 after acquiring an additional 588,294 shares during the period. BlackRock Inc. boosted its stake in shares of BeiGene by 3.8% in the first quarter. BlackRock Inc. now owns 2,699,444 shares of the company's stock worth $509,114,000 after acquiring an additional 98,316 shares during the period. FMR LLC boosted its stake in shares of BeiGene by 3.0% in the third quarter. FMR LLC now owns 2,352,730 shares of the company's stock worth $423,186,000 after acquiring an additional 69,297 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of BeiGene by 68.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 775,857 shares of the company's stock worth $167,222,000 after acquiring an additional 314,764 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of BeiGene by 10.9% in the second quarter. Legal & General Group Plc now owns 284,661 shares of the company's stock worth $46,072,000 after acquiring an additional 27,945 shares during the period. Hedge funds and other institutional investors own 48.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BGNE shares. Bank of America dropped their price objective on BeiGene from $179.30 to $164.30 and set a "neutral" rating for the company in a research note on Monday, April 8th. JPMorgan Chase & Co. increased their price target on BeiGene from $184.00 to $186.00 and gave the company an "overweight" rating in a research note on Tuesday, March 19th. Sanford C. Bernstein dropped their price target on BeiGene from $196.00 to $161.00 and set a "market perform" rating for the company in a research note on Wednesday, March 27th. Finally, Guggenheim dropped their price target on BeiGene from $350.00 to $345.00 and set a "buy" rating for the company in a research note on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $251.70.

Insider Activity

In other news, CEO John Oyler sold 37,668 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total value of $6,178,305.36. Following the sale, the chief executive officer now directly owns 12,332 shares in the company, valued at $2,022,694.64. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO John Oyler sold 37,668 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $164.02, for a total value of $6,178,305.36. Following the sale, the chief executive officer now directly owns 12,332 shares in the company, valued at $2,022,694.64. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The disclosure for this sale can be found here. Insiders sold 64,781 shares of company stock valued at $10,222,381 in the last ninety days. Insiders own 7.40% of the company's stock.

BeiGene Trading Down 3.3 %

Shares of NASDAQ:BGNE traded down $4.83 during trading on Friday, hitting $141.30. The company had a trading volume of 139,454 shares, compared to its average volume of 153,623. The stock has a market cap of $13.51 billion, a price-to-earnings ratio of -16.62 and a beta of 0.61. BeiGene, Ltd. has a one year low of $132.95 and a one year high of $272.49. The company has a fifty day simple moving average of $156.43 and a two-hundred day simple moving average of $169.77. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.32 and a quick ratio of 2.09.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.61) by $0.08. The business had revenue of $634.40 million during the quarter, compared to analyst estimates of $632.52 million. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The company's revenue for the quarter was up 66.9% on a year-over-year basis. During the same period last year, the company earned ($4.29) EPS. As a group, equities analysts forecast that BeiGene, Ltd. will post -8.87 earnings per share for the current year.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.